Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of 20.48% is 22% above its 5-year average of 16.76%, near the high end of its 5-year range (12.02%–21.82%).
As of the fiscal period ended Tuesday, June 30, 2026. 4.80% above its 12-month average of 19.54%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): 20.48%.
RETURN ON EQUITY (ROE)
20.48%
RETURN ON EQUITY (ROE) AVG TTM
19.54%
RETURN ON EQUITY (ROE) AVG 3Y
18.39%
RETURN ON EQUITY (ROE) AVG 5Y
16.76%
RETURN ON EQUITY (ROE) AVG 10Y
17.58%
RETURN ON EQUITY (ROE) AVG 15Y
19.12%
RETURN ON EQUITY (ROE) AVG 20Y
17.91%
CURRENT VS TTM AVG
+4.80%
CURRENT VS 3Y AVG
+11.40%
CURRENT VS 5Y AVG
+22.19%
CURRENT VS 10Y AVG
+16.49%
CURRENT VS 15Y AVG
+7.11%
CURRENT VS 20Y AVG
+14.33%
SECTOR MEDIAN · HEALTHCARE
13.01%
median of 84 covered companies
CURRENT VS SECTOR MEDIAN
+57.43%
vs the sector median at left
United Therapeutics Corporation
Market Cap
$21.10B
Return on Equity (ROE)
20.48%
TTM Avg
19.54%
3Y Avg
18.39%
5Y Avg
16.76%
Market Cap
$20.54B
Return on Equity (ROE)
11.17%
TTM Avg
10.12%
3Y Avg
7.00%
5Y Avg
7.00%
Market Cap
$19.23B
Return on Equity (ROE)
-2.88%
TTM Avg
-13.64%
3Y Avg
-4.29%
5Y Avg
-4.38%
Market Cap
$18.09B
Return on Equity (ROE)
6.39%
TTM Avg
6.40%
3Y Avg
5.73%
5Y Avg
4.16%
Market Cap
$24.30B
Return on Equity (ROE)
-9.62%
TTM Avg
-4.55%
3Y Avg
10.63%
5Y Avg
21.70%
Market Cap
$24.37B
Return on Equity (ROE)
18.89%
TTM Avg
16.95%
3Y Avg
19.08%
5Y Avg
20.56%
Market Cap
$24.62B
Return on Equity (ROE)
25.41%
TTM Avg
12.92%
3Y Avg
11.29%
5Y Avg
9.83%
Market Cap
$25.55B
Return on Equity (ROE)
11.65%
TTM Avg
9.71%
3Y Avg
9.35%
5Y Avg
12.84%
Market Cap
$16.40B
Return on Equity (ROE)
113.29%
TTM Avg
73.63%
3Y Avg
65.34%
5Y Avg
49.74%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| United Therapeutics Corporation (UTHR) | $21.10B | 20.48% | 19.54% | 18.39% | 16.76% |
| STERIS plc (STE)vs › | $20.54B | 11.17% | 10.12% | 7.00% | 7.00% |
| Viatris Inc. (VTRS)vs › | $19.23B | -2.88% | -13.64% | -4.29% | -4.38% |
| Zimmer Biomet Holdings, Inc. (ZBH)vs › | $18.09B | 6.39% | 6.40% | 5.73% | 4.16% |
| BioNTech SE (BNTX)vs › | $24.30B | -9.62% | -4.55% | 10.63% | 21.70% |
| West Pharmaceutical Services, Inc. (WST)vs › | $24.37B | 18.89% | 16.95% | 19.08% | 20.56% |
| Incyte Corporation (INCY)vs › | $24.62B | 25.41% | 12.92% | 11.29% | 9.83% |
| Labcorp Holdings Inc. (LH)vs › | $25.55B | 11.65% | 9.71% | 9.35% | 12.84% |
| Medpace Holdings, Inc. (MEDP)vs › | $16.40B | 113.29% | 73.63% | 65.34% | 49.74% |
| Quest Diagnostics Incorporated (DGX)vs › | $25.94B | 14.13% | 13.34% | 14.07% | 18.07% |
ROE
20.5%
ROA
18.2%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | 20.48% |
| 2026-03-31 | 21.82% |
| 2025-12-31 | 18.81% |
| 2025-09-30 | 19.30% |
| 2025-06-30 | 17.31% |
| 2025-03-31 | 17.79% |
| 2024-12-31 | 18.55% |
| 2024-09-30 | 18.21% |
| 2024-06-30 | 18.77% |
| 2024-03-31 | 19.68% |
| 2023-12-31 | 16.46% |
| 2023-09-30 | 15.75% |
| 2023-06-30 | 16.11% |
| 2023-03-31 | 14.22% |
| 2022-12-31 | 15.16% |
| 2022-09-30 | 15.51% |
| 2022-06-30 | 14.61% |
| 2022-03-31 | 16.46% |
| 2021-12-31 | 12.02% |
| 2021-09-30 | 12.07% |
| 2021-06-30 | 12.94% |
| 2021-03-31 | 11.77% |
| 2020-12-31 | 15.16% |
| 2020-09-30 | 14.27% |
| 2020-06-30 | 13.89% |
| 2020-03-31 | 17.90% |
| 2019-12-31 | -3.76% |
| 2019-09-30 | -3.38% |
| 2019-06-30 | -4.59% |
| 2019-03-31 | -6.41% |
| 2018-12-31 | 21.13% |
| 2018-09-30 | 20.02% |
| 2018-06-30 | 27.57% |
| 2018-03-31 | 20.25% |
| 2017-12-31 | 19.88% |
| 2017-09-30 | 24.37% |
| 2017-06-30 | 21.99% |
| 2017-03-31 | 31.63% |
| 2016-12-31 | 38.33% |
| 2016-09-30 | 38.28% |
| 2016-06-30 | 55.62% |
| 2016-03-31 | 52.46% |
| 2015-12-31 | 40.74% |
| 2015-09-30 | 44.81% |
| 2015-06-30 | 16.45% |
| 2015-03-31 | 16.72% |
| 2014-12-31 | 26.87% |
| 2014-09-30 | 15.93% |
| 2014-06-30 | 23.23% |
| 2014-03-31 | 18.40% |
| 2013-12-31 | 13.38% |
| 2013-09-30 | 22.03% |
| 2013-06-30 | 24.96% |
| 2013-03-31 | 25.48% |
| 2012-12-31 | 27.81% |
| 2012-09-30 | 24.92% |
| 2012-06-30 | 26.81% |
| 2012-03-31 | 26.57% |
| 2011-12-31 | 22.97% |
| 2011-09-30 | 16.98% |
| 2011-06-30 | 13.92% |
| 2011-03-31 | 11.19% |
| 2010-12-31 | 11.98% |
| 2010-09-30 | 11.07% |
| 2010-06-30 | 8.34% |
| 2010-03-31 | 3.46% |
| 2009-12-31 | 2.98% |
| 2009-09-30 | -9.12% |
| 2009-06-30 | -9.53% |
| 2009-03-31 | -7.10% |
| 2008-12-31 | -8.43% |
| 2008-09-30 | 9.64% |
| 2008-06-30 | 11.71% |
| 2008-03-31 | 10.43% |
| 2007-12-31 | 6.71% |
| 2007-09-30 | 34.85% |
| 2007-06-30 | 37.44% |
| 2007-03-31 | 42.42% |
| 2006-12-31 | 36.15% |
| 2006-09-30 | 17.40% |
| 2006-06-30 | 18.41% |
| 2006-03-31 | 20.91% |
| 2005-12-31 | 23.63% |
| 2005-09-30 | 17.83% |
| 2005-06-30 | 15.22% |
| 2005-03-31 | 12.28% |
| 2004-12-31 | 8.06% |
| 2004-09-30 | 2.98% |
| 2004-06-30 | -1.33% |
| 2004-03-31 | -5.33% |
| 2003-12-31 | -5.94% |
| 2003-09-30 | -5.52% |
| 2003-06-30 | -11.92% |
